



Oral Program			
Thursday October 5 th , 2017			
08:00-19:00	Registration		(CIS Building)
09:00-09:30	Poster Session # 1 set up		(CIS Building)
09:30-10:00	Welcome Coffee (CIS Building)		Sponsored By: GSK
10:00-10:10	Opening Remarks		(CIS Building)
	ISV Congress Co-chairs: Denise Doolan, David Weiner, Christiane Gerke, Frédéric Tangy		
10:10-10:30	Opening Talk: The future of vaccines and immunotherapy: challenges, solutions, issues, and the role of ISV		(CIS Building)
	Margaret Liu, <i>ISV President</i>		
10:30-12:00	PLENARY SESSION 1: Innovative Clinical Designs and Human Challenge Models to Accelerate Efficacy Testing		(CIS Building)
	Session Chairs: Denise Doolan, <i>James Cook University</i> ; and Frédéric Tangy, <i>Institut Pasteur</i>		
10:30-11:00	[PL1.1] How to Tackle the Most Successful Pathogen on Earth: Tuberculosis vaccine and biomarker development		
	Stefan Kaufmann, <i>Max Planck Institute for Infection Biology</i>		
11:00-11:30	[PL1.2] Phase IIb Test of Concept studies for HIV		
	Peter Gilbert, <i>Fred Hutchinson Cancer Research Center</i>		
11:30-12:00	[PL1.3] Lessons learned from Ebola Vaccine R&D during a public health emergency		
	Marie-Paule Kieny, <i>Inserm</i>		
12:00-12:30	[PL1.4] Pandemic Challenges: Middle East Respiratory Syndrome coronavirus (MERS CoV)		
	Jerome Kim, <i>International Vaccine Institute</i>		
12:30-13:30	Lunch ("Social – Modules" Building)		Sponsored By: Inovio Pharmaceuticals, Inc.
13:30-15:30	Concurrent Session 1 <i>(CIS Building)</i> Maternal and Neonate Immunization Session Chairs: Kathrin Jansen, <i>Pfizer</i> ; and Shabir Madhi, <i>University of Witwatersrand</i>	Concurrent Session 2 <i>(Duclaux Building)</i> Institut Pasteur – Bringing Vaccinology to the World Session Chairs: Armelle Phalipon and Frédéric Tangy, <i>Institut Pasteur</i>	Concurrent Session 3 <i>(François Jacob Building)</i> Structural Vaccinology and Protective Monoclonal Antibodies Session Chairs: Florian Krammer, <i>Icahn School of Medicine at Mount Sinai</i> ; and Joon Haeng Rhee, <i>Chonnam National University Medical School</i>
13:30-13:55	[O1.1] Progress on Clinical trials of RSV, influenza and pertussis vaccines in pregnancy Shabir Madhi, <i>University of Witwatersrand</i>	[O2.1] ADVAC: Lessons from 18 years of advanced training in vaccinology Paul-Henri Lambert, <i>University of Geneva</i> 13:30-13:50	[O3.1] Lesson from the analysis of the immune response to <i>Plasmodium falciparum</i> Antonio Lanzavecchia, <i>ETH Zurich</i>
13:55-14:20	[O1.2] Perinatal and neonatal infection prevention: Group B streptococcus vaccines Paul Heath, <i>St Georges Hospital</i>	[O2.2] The annual vaccinology in Africa course Adrian Hill, <i>University of Oxford</i> 13:50-14:10	[O3.2] Epitope-focused vaccine design to protect against Zika and dengue virus simultaneously Felix Rey, <i>Institut Pasteur</i>

14:20-14:35	[O1.3] Updates on the Development of a Multivalent Group B Streptococcal vaccine <i>Annaliesa Anderson, Pfizer</i>	[O2.3] Institut Pasteur Vaccinology Course Armelle Phalipon, Frederick Tangy, <i>Institut Pasteur</i> 14:10-14:30	[O3.3] Analysis of antibody repertoires reshaped by vaccination with respiratory syncytial virus post fusion protein Gerald Schneikart, <i>GSK</i>
14:35-14:50	[O1.4] Induction of epithelial cell-neutralizing antibodies against cytomegalovirus (CMV) in adults vaccinated with an enveloped virus-like particle (eVLP) containing an optimized form of glycoprotein b for prophylactic vaccination against CMV Joanne M. Langley, <i>Dalhousie University</i>	[O2.4] IMVACC: a web-based international master in vaccinology Jean-Pierre Kraehenbuhl, <i>HSeT</i> 14:30-14:50	[O3.4] A novel approach to unravel the effective human antibody response induced by natural infection or vaccination against respiratory syncytial virus (RSV) Emanuele Andreano, <i>University of Siena (IT)</i>
14:50-15:05	[O1.5] The Importance of RSV F protein conformation in stimulation of protective immune responses in animals previously infected with RSV Trudy Morrison, <i>University of Massachusetts Medical School</i>	[O2.5] A bacterial protease inhibitor as vaccine adjuvant Lorena Coria, <i>Universidad Nacional de San Martín</i> 14:50-15:00	[O3.5] Engineering transient production of HIV-1 broadly neutralizing antibodies by DNA encoded monoclonal antibody technology (dMabs) Megan Wise, <i>Inovio Pharmaceuticals</i>
15:05-15:20	[O1.6] Epitope-specific antibody responses to HSV-2 glycoprotein D immunization differs depending on the adjuvant Sita Awasthi, <i>University of Pennsylvania</i>	[O2.6] Developing a universal flu vaccine: multifunctional T cells and multidisciplinary consortia Ajibola Omokanye <i>University of Gothenburg</i> 15:00-15:10	[O3.6] Conversion of a DNA-encoded monoclonal antibody (dMAb) into scFv-Fc format improves expression and protects against lethal Zika virus challenge following <i>in vivo</i> gene delivery in a mouse model Stephanie Ramos, <i>Inovio Pharmaceuticals</i>
	-----	[O2.7] Vaccine approaches against leishmaniasis Rafael de Freitas e Silva, <i>Aggeu Magalhães Institut</i> 15:10-15:20	-----
	-----	[O2.8] Lessons for developing countries – introduction of 6 new vaccines into a national program in less than a decade Chandrakant Lahariya, <i>World Health Organization</i> 15:20-15:30	-----
15:30-16:00	Coffee Break (CIS Building) Sponsored By: Green Cross Corporation		
16:00-18:00	PLENARY SESSION 2: Vaccines as Solutions to AMR Threats (CIS Building) Session Chair: Danilo Casimiro, <i>Aeras</i> ; and Peter Hotez, <i>Baylor College of Medicine</i>		
16:00-16:10	[PL2.1] Introductory Overview Danilo Casimiro, <i>Aeras</i>		

16:10-16:40	[PL2.2] The role of vaccines in fighting antimicrobial resistance Kathrin Jansen, <i>Pfizer</i>
16:40-17:10	[PL2.3] Prevention of tuberculosis in rhesus macaques by a cytomegalovirus-based vaccine Louis Picker, <i>Oregon Health & Science University</i>
17:10-17:25	[PL2.4] A recombinant fimbrial prototype vaccine administered by intradermal route protects <i>Aotus nancymae</i> non-human primates from ETEC diarrhea Geneviève Renauld-Mongénie, <i>Sanofi-Pasteur</i>
17:25-17:40	[PL2.5] Safety, tolerability and immunogenicity of ExPEC4V (JNJ-63871860) vaccine for prevention of invasive extraintestinal pathogenic <i>Escherichia coli</i> disease: a phase 1, double-blind, placebo-controlled study in healthy Japanese participants Patricia Ibarra de Palacios, <i>Janssen Vaccines</i>
17:40-17:55	[PL2.6] New promising targets for synthetic Omptin-based peptide vaccine against Gram-negative pathogens Valentina Feodorova, <i>Saratov Research Veterinary Institute</i>
18:00-19:00	Poster Session # 1: Authors present at their posters <i>(CIS Building)</i>
18:30-20:00	Welcome Reception <i>(CIS Building)</i> Sponsored By: EpiVax, Inc.
Friday, October 6th, 2017	
08:00-10:15	PLENARY SESSION 3: Emerging Infectious Diseases <i>(CIS Building)</i> Session Chairs: Shan Lu, <i>UMass Medical School</i> ; and Marie-Paule Kieny, <i>Inserm</i>
08:00-08:25	[PL3.1] Vesicular Stomatitis Virus Vectors – a promising vaccine platform Heinz Feldmann, <i>NIAID, National Institutes of Health</i>
08:25-08:50	[PL3.2] Rapid vaccine development against emerging viruses on the long road to availability; Ebola and Zika Gary Kobinger, <i>Centre for Research in Infectious Diseases</i>
08:50-09:05	[PL3.3] A Phase 1 clinical trial of a Hantaan virus, Puumala virus, and Hantaan/Puumala virus DNA vaccine delivered by disposable syringe jet injection: preliminary findings Jay Hooper, <i>US Army Medical Research Institute of Infectious Disease</i>
09:05-09:20	[PL3.4] Development of novel and safe single-dose vaccines; preclinical efficacy data for Zika, Ebola and Lassa fever Farshad Guirakhoo, <i>Geovax, Inc.</i>
09:20-09:35	[PL3.5] A single-round infectious particle Zika virus vaccine candidate Karin B. Sundstrom, <i>Duke-NUS Medical School</i>
09:35-09:50	[PL3.6] Durability and correlates of vaccine protection against Zika virus in rhesus monkeys Peter Abbink, <i>Beth Israel Deaconess Medical Center</i>
09:50-10:05	[PL3.7] A synthetic, consensus DNA vaccine against Zika virus, GLS-5700, is highly immunogenic in humans and induces antibody responses that are protective in a passive transfer mouse challenge model Emma Reuschel, <i>The Wistar Institute</i>
10:15-10:45	Coffee Break <i>(CIS Building)</i> Sponsored By: Sanofi Pasteur
10:45-12:30	PLENARY SESSION 4: Novel Vaccine Concepts / Emerging Technologies <i>(CIS Building)</i> Session Chair: Jeffrey Ulmer, <i>GSK</i> ; and Connie Schmaljohn, <i>USAMRIID</i>
10:45-11:10	[PL4.1] A.I.R vaccines – A synthetic self-amplifying RNA-based vaccine platform Stephanie Erbar, <i>BioNTech RNA Pharmaceuticals</i>
11:10-11:35	[PL4.2] Delivery systems for RNA Therapy, RNA vaccines and in vivo gene editing Daniel Anderson, <i>Massachusetts Institute of Technology</i>
11:35-11:50	[PL4.3] DNA-launched RNA replicon vaccines induce potent anti-Ebola virus immune responses that can be further improved by protein or MVA boosts Karl Ljungberg, <i>Karolinska Institute</i>
11:50-12:05	[PL4.4] Thermostable plasmid DNA launches a live-attenuated yellow fever vaccine platform that induces protection in vivo Kai Dallmeier, <i>University of Leuven</i>

12:05-12:20	<p>[PL4.5] A combination heroin-HIV vaccine abrogates nociceptive and locomotive effects of heroin and induces cross-reactive antibodies to other abused prescription opioids and to the v2-loop of the HIV-1 envelope protein Gary Matyas, <i>Walter Reed Army Institute of Research</i></p>		
12:30-13:30	<p>Lunch ("Social – Modules" Building)</p>		<p>Sponsored By: VGXI, Inc.</p>
(13:30)	<p>Posters to be taken down from Poster Session # 1; Poster Session # 2 set up (CIS Building)</p>		
13:30-14:45	<p>Poster Session # 2: Authors present at their posters (CIS Building)</p>		
14:30-15:00	<p>Coffee Break (CIS Building)</p>		<p>Sponsored By: Eurogentec</p>
14:45-15:45	<p>ISV Annual General Meeting (CIS Building)</p>		
16:00-18:15	<p>Concurrent Session 4 (CIS Building) Vaccines for the Elderly Session Chairs: Tonya Villafana, <i>Medimmune</i>; and Gary Kobinger, <i>Centre for Research in Infectious Diseases</i></p>	<p>Concurrent Session 5 (Duclaux Building) Mucosal Vaccination Session Chairs: Linda Klavinskis, <i>King's College London</i>; and Hiroshi Kiyono, <i>University of Tokyo</i></p>	<p>Concurrent Session # 6 (François Jacob Building) Systems Vaccinology and Computational Vaccinology Session Chairs: Annie de Groot, <i>EpiVax Inc.</i></p>
16:00-16:25	<p>[O4.1] HZ/su: an innovative approach to the prevention of Herpes Zoster Jacqueline Miller, <i>GSK</i></p>	<p>[O5.1] Cutting edge of the mucosal immune system for the development of oral and nasal vaccines Hiroshi Kiyono, <i>University of Tokyo</i></p>	<p>[O6.1] Human Vaccines Project: decoding the human immune system to accelerate next generation vaccine development Stacey Wooden, <i>Human Vaccines Project</i></p>
16:25-16:50	<p>[O4.2] RSV vaccines in the elderly: a challenge for development, the MEDI7510 story Tonya Villafana, <i>Medimmune</i></p>	<p>[O5.2] Challenges in developing mucosal vaccines against global infections Cecil Czerkinsky, <i>CNRS-INSERM-University of Nice</i></p>	<p>[O6.2] Systems approaches highlight the many facets of interferons in infections and in vaccine mediated protection Rafick-Pierre Sékaly, <i>Case Western Reserve</i></p>
16:50-17:15	<p>[O4.3] Vision for adult vaccination Kathrin Jansen, <i>Pfizer</i></p>	<p>[O5.3] Flagellin-based recombinant divalent vaccines induce protective immune responses in a Porphyromonas gingivalis and Fusobacterium nucleatum mixed infection model in mice Joon Haeng Rhee, <i>Chonnam National University Medical School</i></p>	<p>[O6.3] Milieu Intérieur: defining the boundaries of a healthy immune response for a better understanding of disease Darragh Duffy, <i>Institut Pasteur</i></p>
17:15-17:30	<p>[O4.4] Benefits of high dose Fluzone® Influenza vaccine for anti-neuraminidase immune responses in the elderly Anne-Gaëlle Bebin-Blackwell, <i>University of Georgia</i></p>	<p>[O5.4] Food grade live oral mucosal vaccine (LacVax™:OmpA) against Shigella: affordable strategies for effective immunisation Priti Desai, <i>B.V. Patel PERD Centre</i></p>	<p>[O6.4] Computational vaccine design for humans and animals using the iVAX toolkit Frances Terry, <i>EpiVax Inc.</i></p>

17:30-17:45	[O4.5] Zoster vaccine effectiveness against incident herpes zoster and risks of vaccine failure in elderly in the UK Maria Alexandridou, <i>P95</i>	[O5.5] Efficacy of novel epithelial stem cell-based AIDS vaccine to induce mucosal immune responses and protect against repeated low dose SIV challenge Marie-Claire Gauduin, <i>Texas Biomedical Research Institute</i>	[O6.5] Computational vaccinology for the design of personalized cancer therapies: from infectious disease to cancer vaccines Guilhem Richard, <i>EpiVax Inc.</i>
17:45-18:00	[O4.6] MVA-BN®-RSV Vaccine boosts pre-existing RSV immunity in young adult and elderly mice Yvonne Wollmann, <i>Bavarian Nordic GmbH</i>	[O5.6] A novel mucosal HIV vaccination regimen to elicit protective HIV-specific immunity Branka Grubor-Bauk, <i>University of Adelaide</i>	[O6.6] COBRA HA induced hemagglutination-inhibition antibodies against a panel of H3N2 influenza antigenic variants Ted Ross, <i>University of Georgia Center for Vaccines and Immunology</i>
18:00-18:15	[O4.7] Immune responses to intradermal and intramuscular inactivated influenza vaccine among older age group Kobporn Boonnak, <i>Mahidol University</i>	[O5.7] A novel vaccine against <i>Helicobacter pylori</i>-induced gastritis Hafiz Umar Arshad, <i>Murdoch Children's Research Institute</i>	[O6.7] Expanding a web-based programme for identification of invasive <i>M. bovis</i> BCG Lesedi Modipane, <i>University of Pretoria</i>
19:00	Bus leaves from Institut Pasteur for dinner cruise -Tickets Required (Main Entrance)		
19:30	Cruise Departure		
22:30	Bus leaves from pier to return to Institut Pasteur		
Saturday, October 7th, 2017			
08:00-10:00	PLENARY SESSION 5: Neglected and Low and Middle Income Countries (LMIC) Diseases (CIS Building) Session Chairs: Allan Saul, <i>GSK</i> ; and Sarah Gilbert, <i>University of Oxford</i>		
08:00-08:25	[PL5.1] Prioritizing vaccine development for neglected diseases of LMIC Allan Saul, <i>GSK</i>		
08:25-08:50	[PL5.2] The "Antipoverty Vaccines" for Neglected Tropical Diseases Peter Hotez, <i>Baylor College of Medicine</i>		
08:50-09:15	[PL5.3] Affordable vaccines for global health: the Hilleman approach Davinder Gill, <i>Hilleman Laboratories</i>		
09:15-09:30	[PL5.4] First evaluation in humans of a chemically attenuated <i>P. falciparum</i> whole parasite blood-stage vaccine Danielle Staniscic, <i>Griffith University</i>		
09:30-09:45	[PL5.5] Novel subunit-vaccine approaches against tuberculosis Manish Gupta, <i>Jawaharlal Nehru University</i>		
09:45-10:00	[PL5.6] Discovery of Crimean-Congo Hemorrhagic Fever Virus vaccine candidate antigens by protein microarray scanning and verification of the determined antigens by recombinant ELISA Sultan Gulce-Iz, <i>Ege University</i>		
10:00-10:30	Coffee Break (CIS Building) Sponsored By: CTL Europe GmbH		
10:30-12:35	Concurrent Session 7: Cancer Vaccines and Immunotherapy (CIS Building) Session Chairs: David Weiner, <i>The Wistar Institute</i> ; and Joon Haeng Rhee, <i>Chonnam National University Medical School</i>	Concurrent Session 8: Viral Vaccines (Duclaux Building) Session Chairs: Britta Wahren, <i>Karolinska Institute</i> ; and Ted Ross, <i>University of Georgia Center for Vaccines and Immunology</i>	Concurrent Session 9: One Health (François Jacob Building) Session Chairs: Ed Rybicki, <i>University of Cape Town</i> ; and Nathalie Garcon, <i>Bioaster</i>

10:30-10:55	[O7.1] Personalized cancer vaccines Gerald Linette, <i>University of Pennsylvania</i>	[O8.1] The biology of antibody enhanced disease: evidence of increased risk after CYD-TDV vaccination Scott Halstead, <i>Uniformed Services University of the Health Sciences</i>	[O9.1] Evaluation of ChAdOx1 MERS vaccine in camels in Saudi Arabia Naif Alharbi, <i>King Abdullah International Medical Research Center</i> 10:30-10:45
10:55-11:20	[O7.2] Cancer vaccines and immunotherapy- where are we today and where do we go from here? Adil Daud, <i>UCSF Medical Center</i>	[O8.2] Long-term efficacy of a Hepatitis E vaccine Jun Zhang, <i>Xiamen University</i>	[O9.2] Novel universal nanoparticle vaccines for bird flu and coronavirus infections in birds Jianping Li, <i>University of Connecticut</i> 10:45-11:00
11:20-11:35	[O7.3] Clinical and immunologic biomarkers for regression of high grade cervical dysplasia and clearance of HPV16/18 infection after immunotherapy with VGX-3100 in a Phase IIb Clinical Trial Kimberly Kraynyak, <i>Inovio Pharmaceuticals</i>	[O8.3] DNA and protein co-delivery vaccines induce potent immune responses able to delay SIV/SHIV acquisition George Pavlakis, <i>National Cancer Institute at Frederick</i>	[O9.3] The application of NHEJ-CRISPR/Cas9 and Cre-Lox system in the generation of multivalent vaccines against avian influenza virus Pengxiang Chang, <i>The Pirbright Institute</i> 11:00-11.15
11:35-11:50	[O7.4] Synthetic DNA-encoded monoclonal antibody delivery (DMAb) of anti-CTLA4 antibodies induces tumor shrinkage in vivo Elizabeth Duperret, <i>The Wistar Institute</i>	[O8.4] Preclinical assessment of multivalent vaccine vectors against filoviruses Sarah Sebastian, <i>University of Oxford</i>	[O9.4] Immune Engineered H7N9 influenza hemagglutinin overcomes poor vaccine immunogenicity Annie De Groot, <i>EpiVax Inc.</i> 11:15-11:30
11:50-12:05	[O7.5] DNA-based cancer vaccines designed by SynCon® technology break tolerance in genetically diverse pre-clinical models Jian Yan, <i>Inovio Pharmaceuticals</i>	[O8.5] Assessment of protective immunity elicited by chimeric hemagglutinin-based universal influenza virus vaccines against pandemic H1N1 infection in preclinical ferret studies Wen-Chun Liu, <i>Icahn School of Medicine at Mount Sinai</i>	[O9.5] OMV based vaccine formulations against shiga-toxin producing <i>Escherichia coli</i> strains are both protective in mice and immunogenic in calves Matias Fingerhann, <i>Instituto Nacional de Producción de Biológicos</i> 11:30-11:45
12:05-12:20	[O7.6] Synthetic immunogens drive potent antigen specific anti-tumor immune responses Bernadette Ferraro, <i>Inovio Pharmaceuticals</i>	[O8.6] Improved Correlation between Dengue vaccine Clinical Efficacy and Protection in NHP using an intravenous, high-dose challenge model Veronique Barban, <i>Sanofi Pasteur</i>	[O9.6] Impact of obesity on humoral and cellular immune responses to vaccination against tick borne encephalitis Ursula Wiedermann, <i>Medical University Vienna</i> 11:45-12:00

12:20-12:35	[O7.7] Efficacy of consensus DNA-immunization against drug resistance in HIV infection evaluated in a murine tumor model Maria Isaguliantis, <i>Riga Stradins University</i>	[O8.7] Induction of binding and functional antibody responses to HIV-1 envelope V2 peptide with army liposome formulation as the adjuvant Mangala Rao, <i>Walter Reed Army Institute of Research</i>	[O9.7] Vaccine batch to vaccine batch comparison by consistency testing (VAC2VAC) Hilde Depraetere, <i>European Vaccine Initiative</i> 12:00-12:15
	-----	-----	[O9.8] Prevention of viral vector aggregation and maintenance of antigenicity and infectivity by means of the amino acid-based SPS® formulation technology platform Martin Scholz <i>LEUKOCARE AG</i> 12:15-12:30
12:45-14:00	Lunch (“Social – Modules” Building)		Sponsored By: Pfizer
13:15-14:00	Career Development Panel and “Meet the ISV Fellows” (during lunch)		<i>(CIS Building)</i>
14:00-14:30	ISV Award Ceremony Chairs: Denise Doolan and David Weiner		<i>(CIS Building)</i>
14:30-15:30	PLENARY SESSION 6: Public Private Partnerships Session Chairs: Margaret Liu, <i>ProTherImmune</i> ; and David Weiner, <i>The Wistar Institute</i>		<i>(CIS Building)</i>
14:30-14:40	[PL6.1] Nathalie Garcon, Bioaster		
14:40-14:50	[PL6.2] Allan Saul, GSK Vaccines Institute for Global Health		
14:50-15:00	[PL6.3] Odile Leroy, European Vaccine Initiative		
15:00-15:10	[PL6.4] ADVANCE governance framework for public-private collaborations: Towards strengthening vaccine benefit-risk monitoring in Europe Laurence Torcel-Pagnon, <i>Sanofi Pasteur</i>		
15:10-15:50	OPEN DISCUSSION WITH ALL PARTICIPANTS		<i>(CIS Building)</i>
15:50-16:00	Closing Remarks: Denise Doolan and David Weiner Introduction to 2018 ISV Annual Congress – Ted Ross, <i>University of Georgia</i>		<i>(CIS Building)</i>